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INTRODUCTION
Cardiovascular disease is the leading
cause of death for both men and women in
much of the Western world and is pre-
dicted to be the leading global killer by
2020 (1). Atherosclerosis is responsible for
coronary heart disease, most strokes and
limb ischemia. A large number of studies
have shown thrombosis to result from
plaque instability. Thrombotic events (that
follow fissure or rupture of the fibrous cap
with propagation of the thrombus up-
stream from the site of cap rupture) are the
underlying basis for acute disease in the
majority of cases involving atherosclerosis
(2). Thus, understanding atherosclerotic
plaque stability is highly relevant. Plaques
that rupture show increased adventitial
and plaque neovascularization, suggesting
that neoangiogenesis contributes to their
instability (3) and anti-neoangiogenic ther-
apy is emerging as a promising novel av-
enue for treating plaque instability (4,5).
This approach is hampered by lack of in-
sight into the activity of endogenous an-
giogenic signaling pathways.
Among the molecular signals involved
in revascularization, the Hedgehog (HH)
pathway is featured prominently (6). HH
constitutes a family of highly hydropho-
bic secreted morphogenetic hormones of
which in humans three isoforms exist:
Sonic (SHH), Indian (IHH) and Desert
(DHH) (7). Their functions include main-
tenance of the endothelial compartment
and orchestrating revascularization upon
vessel occlusion–induced ischemia (8).
After delivery to target cells, HH binds
to its transmembrane receptor Patched-1
(PTCH1). Under HH-unligated condi-
tions, PTCH1 keeps a second transmem-
brane receptor called Smoothened (SMO)
inactive (9). In mammals, this probably
involves translocation of a vitamin
D3–like 3-β hydroxysteroid (10). After
binding of HH to PTCH1, this inhibition
is relieved and SMO subsequently initi-
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ates signaling through the glioma-
 associated (GLI) transcription factors, re-
sulting in the transcription of target
genes, including both GLI1 and PTCH1
(Figure 1) (10). The in vivo relevance of
the induction of these genes was proven
in ischemia experiments, in which in-
tramyocardial gene transfer of SHH pro-
moted recovery and preservation of left
ventricular function in myocardial ische-
mia by enhanced neovascularization (11),
supporting the notion that HH aids in is-
chemic tissue rescue and especially in its
revascularization. In agreement, HH pro-
duction is critical for VEGF production
(9,12) and endothelial maintenance and
growth (9,13–17). From this, we can infer
that HH signaling may well play a detri-
mental role as well, causing revascular-
ization-mediated plaque instability, and
constitutes an attractive candidate for
targeting pathological neovascularization
(18). Importantly, the activity of the HH
pathway in atherosclerotic structures has
not been investigated.
These considerations prompted us to
investigate the activity of the HH path-
way in healthy human vessels as well as
in atherosclerotic pathology. We found
that normal vessels are characterized by
substantial HH pathway activity in re-
sponse to ligand present in this tissue,
but that in atherosclerotic plaques, this
activity is downregulated, leading to a
functional dichotomy. We propose that
the downregulation of HH activity in
plaques, despite the presence of ligand,
may serve as a protective response of the
body to mitigate the risk posed by ather-




To obtain healthy vessels, slices of
renal arteries from family kidney trans-
plantation donors were stored in cold
preservation solution, and vessels were
prepared by removing connective tissue,
fat and lateral vessels. After opening
each vessel lengthwise, the adventitia
side was dried with sterile gauze. One
layer of the gauze was left on the adven-
titia side and cut off around the vessel,
after which material was stored at –80°C.
Carotid plaques were obtained from sub-
jects undergoing carotid endarterectomy
for symptomatic high-grade stenosis of
the internal carotid artery. Plaques were
freshly harvested and divided into sec-
Figure 1. High activity of the HH pathway is characteristic of healthy human vessels. (A)
Schematic depiction of HH signal transduction in the absence (left panel) and presence
of ligand (right panel). (B) Comparison of GAPDH and RFLP0 expression levels in healthy
vessels and plaques. HH pathway target genes GLI1 (C, D) and PTCH1 (E, F) transcript lev-
els were correlated with the expression levels of IHH (C, E) and DHH (D, F) in renal arteries
from four healthy organ donors. (G) HH pathway activity in renal arteries from 10 healthy
organ donors (sequentially numbered) was assessed using Western blot for the target
genes. (H) Human coronary endothelial cells were cultured according to routine proce-
dures for 24 h with either vehicle control or recombinant ShhN (1 μg/mL). Cell viability was
evaluated by MTT reduction. Data are means ± standard error of the mean (n = 3) (p <
0.05). Because expression levels of the routinely used GAPDH housekeeping gene may be
changed depending on HH pathway activity, we first compared GAPDH levels with RPLP0
levels, since the latter gene was suggested to be a better housekeeping gene when
studying HH pathway activity (27). As shown in (B), GAPDH and RPLP0 levels correlate well
in all samples used for this study, and we thus considered GAPDH an appropriate house-
keeping gene.
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tions of 5-mm thickness and stored at
–80°C. Percutaneous coronary atherec-
tomy was performed in de novo lesions by
means of a pullback atherectomy catheter
(Arrow, Reading, PA, USA). Briefly, this
10-french compatible over-the-wire
catheter is positioned beyond the lesion
to treat. After the cutting blade is exposed
and on-axis high-speed rotation is
started, the catheter is gently withdrawn
by manual pullback. This procedure al-
lows complete circumferential cuts along
the whole length of the lesion, thus pro-
viding in vivo plaque samples, suitable
for analysis. In all patients, one biopsy
was taken out of the culprit lesion. All
studies were done according to national
and institutional ethical guidelines.
Quantitative Reverse Transcriptase–
Polymerase Chain Reaction
RNA isolation from clinical samples
was performed using TRIzol according to
the manufacturer recommendations. The
RNA was dissolved in 30 μL RNAse-free
water and stored at –80°C. RNA concen-
tration was checked using a Nanodrop
spectrophotometer (Isogen, Life Science,
De Meern, the Netherlands). For cDNA
synthesis, 1 μg RNA was used with an
end volume of 20 μL. Subsequently,
quantitative polymerase chain reactions
(PCRs) detecting the expression level of
different proteins were performed on a
Roche LightCycler 480 system using the
following primers (“h” stands for
“human”): hRPLP0 (RPLP0: ribosomal
protein, large, P0) forward, GGCAC
CATTG AAATC CTGAG TGATG TG;
hRPLP0 reverse, TTGCG GACAC
CCTCC AGGAAGC; hGAPDH forward,
AAGGT GAAGG TCGGA GTCAA C;
hGAPDH reverse, TGGAA GATGG
TGATG GGATT; hGLI1 forward, GTTCA
CATGC GCAGA CACAC T; hGLI1 re-
verse, TTCGA GGCGT GAGTA TGACT
T; hPTCH1 forward, CGGCA GCCGC
GATAA G; hPTCH1 reverse, TTAAT
GATGC CATCT GCATC C; hSHH for-
ward, GCTCG GTGAA AGCAG
AGAAC; hSHH reverse, CCAGG
AAAGT GAGGA AGTCG; hIHH for-
ward, CACCC CCAAT TACAA TCCAG;
hIHH reverse, CGGTC TGATG TGGTG
ATGTC; hDHH forward, ACCAA TCTAC
TGCCC CTGTG; hDHH reverse, GTTGT
AGTTG GGCAC GAGGT.
Cell Culture and MTT Assay
Primary human coronary arterial en-
dothelial cultures (HCAECs) were main-
tained per provider suggestions (Lonza,
Verviers, Belgium). In short, HCAECs
were grown in EGM-2MV medium
(Lonza, Verviers, Belgium) supplemented
with 5% fetal calf serum, growth factors,
hydrocortisone and gentamicine, at 37°C
in a 5% CO2 humidified atmosphere.
After treatment with recombinant human
Shh-N (R&D Systems, Minneapolis, MN,
USA), HCAEC viability was determined
by a routine 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT)
assay as described by Queiroz et al. (13).
Western Blotting Analysis
Plaques and healthy vessels were 
lysed in lysis buffer (50 mmol/L Tris
[Tris(hydroxymethyl)aminomethane]-HCl
[pH 7.4], 1% Tween 20, 0.25% sodium de-
oxycholate, 150 mmol/L NaCl, 1 mmol/L
EGTA [ethylene glycol tetra acetic acid], 
1 mmol/L o-vanadate, 1 mmol/L NaF
and protease inhibitors [1 μg/mL apro-
tinin, 10 μg/mL leupeptin and 1 mmol/L
4-{2-amino-ethyl}-benzolsulfonyl-fluoride-
 hydrochloride]) on ice. Subsequently,
samples were cleared by centrifugation
and dissolved in an equal volume of 2×
sodium dodecyl sulfide (SDS) gel loading
buffer (100 mmol/L Tris-HCl [pH 6.8],
200 mmol/L dithiothreitol, 4% SDS, 
0.1% bromophenol blue and 20% glycerol)
and boiled for 5 min. Thereafter, proteins
were resolved on molecular size using
SDS polyacrylamide gel electrophoresis
and analyzed by Western blot essentially
as described previously (19). Briefly,
membranes were blocked in 1% fat-free
dried milk or bovine serum albumin (2%)
in Tris-buffered saline (TBS)/0.1% Tween
20 (TBST) and incubated overnight at 4°C
with the appropriate primary antibody.
Primary antibodies against GLI1 (#2553)
and PTCH1 (#2468) were obtained from
Cell Signaling Technology (Beverly, MA,
USA). Anti-HH (5E1; recognizing IHH,
DHH and SHH) (20) antibody was pur-
chased from the Developmental Hybri -
doma Bank (Iowa City, IA, USA), respec-
tively. After incubation, membranes were
washed in TBST and incubated with anti-
rabbit, anti-goat and anti-mouse horserad-
ish peroxidase–conjugated secondary an-
tibodies at 1:2,000 dilutions in blocking
buffer for 1 h. Blots were imaged using
LumiLight Plus ECL (Roche, Basel, Switz-
erland). Despite the absence of calcium or
zinc salts from our buffers (21), we ob-
served efficient immunodetection of HH
ligands using the 5E1 antibody, as also
shown previously by Lee et al. (22) and
Kohtz et al. (23).
Figure 2. Abundant presence of HH ligands in atherosclerotic plaques. (A) Coronary
plaques were collected from 17 patients by catheterization, and protein levels of HH lig-
ands were analyzed by Western blot. (B) Carotid plaques were collected by endarterec-
tomy and analyzed for the levels of HH protein using Western blot. Immature forms (as de-
duced from apparent molecular weight) are abundantly present in plaques. Carotid
plaques also contain abundant HH. Thus, atherosclerotic plaques are characterized by
the presence of HH ligands.
R E S E A R C H  A R T I C L E
M O L  M E D  1 8 : 1 1 2 2 - 1 1 2 7 ,  2 0 1 2  |  Q U E I R O Z  E T  A L .  |  1 1 2 5
Analysis of Vitamin D3 in Lipoproteins
Isolation of lipoproteins was per-
formed as described by Queiroz et al.
(13), and radioimmunoassay for mea-
surement of vitamin D3 was performed
as described earlier (24–26).
RESULTS
Healthy Human Vessel Is
Characterized by Strong Constitutive
Activation of HH Signaling
The vascular network is widely recog-
nized to be targeted by HH ligands, since
these morphogens constitute an impor-
tant angiogenic signal after ischemic
stress (11), but the activation status of the
HH pathway in otherwise unchallenged
healthy human vessel remains uncertain.
Hence, we isolated the renal artery from
healthy multiorgan donors and investi-
gated these for HH signaling activity by
assessing relative mRNA expression lev-
els of the HH pathway targets PTCH1
and GLI1. Because expression levels of
the routinely used GAPDH housekeeping
gene may change depending on HH
pathway activity, we first compared
GAPDH levels with RPLP0 levels, since
the latter gene has been suggested to be
a better housekeeping gene when study-
ing HH pathway activity (27). As shown
in Figure 1B, GAPDH and RPLP0 levels
correlate well in all samples used for this
study, and we thus considered GAPDH
to be an appropriate housekeeping gene.
Healthy vessels showed high expres-
sion of GLI1 and PTCH1, and these ex-
pression levels positively correlated with
the expression levels of IHH and DHH
(Figures 1C–F). SHH transcript levels
were below detection levels. To confirm
these observations, we analyzed PTCH1
and GLI1 protein levels in 10 healthy
vessels by Western blot analysis (Fig-
ure 1G). PTCH1 and GLI1 protein levels
were easily detectable in healthy vessels,
although we did observe large interpa-
tient variability. A subsequent study in
aortic, carotid and femoral artery seg-
ments (29 samples obtained during au-
topsy) showed that the HH ligand was
abundant in all arteries studied (data not
shown). Interestingly, pharmacological
inhibition of HH signaling using either
cyclopamine (28) or vitamin D (29) was
previously shown to compromise sur-
vival of primary coronary artery en-
dothelial cells (13), suggesting that HH
signaling is not only active in this cell
type, but also required for endothelial
maintenance. In line with these data,
treatment of primary coronary artery
 endothelial cells with recombinant sonic
hedgehog N-terminus (ShhN) induced
increased cell viability relative to control
treated cells (Figure 1H). This finding
confirms a recent report showing that
HH signaling is important for vascular
integrity in the murine coronary circula-
tion (30) and suggests that activation of
HH signaling is a general feature of the
human  vasculature.
Presence of HH Ligand in
Atherosclerotic Plaques
Subsequently, we investigated the
presence of HH ligands in atheroscle-
rotic structures. To this end, material ob-
tained from 17 coronary plaques was
collected and subjected to Western blot
analysis for HH ligand (Figure 2A). This
analysis revealed local production of
HH during atherosclerotic plaque
 formation.
The presence of HH ligand was con-
firmed by Western blot analysis on ather-
osclerotic carotid plaques (Figure 2B).
Thus, locally produced HH ligand is
present in substantial amounts in athero-
sclerotic structures in human vessels,
Figure 3. Absence of response to HH ligands in atherosclerotic plaques. (A) Atheroscle-
rotic plaques were collected from 24 patients undergoing carotid endarterectomy for
symptomatic high-grade stenosis of the internal carotid artery. Renal arteries from four
family kidney transplantation donors were used as healthy control vessels. HH ligand ex-
pression and pathway activity was assessed by quantitative reverse transcriptase PCR. Ex-
pression of HH pathway targets GLI1 (B) and PTCH1 (C), as determined by quantitative re-
verse transcriptase PCR, was correlated with the expression level of HH ligands in
 atherosclerotic plaques. (D) The low levels or absence of HH target gene products were
confirmed by Western blotting analysis in the same 24 subjects. (E) Radioimmunoassay
analysis of three major plasma lipoproteins reveals that LDL contains the highest concen-
trations and VLDL the lowest levels of the endogenous HH signaling antagonist 25-OH vita-
min D3 (25-OHvitD3).
1 1 2 6 |  Q U E I R O Z  E T  A L .  |  M O L  M E D  1 8 : 1 1 2 2 - 1 1 2 7 ,  2 0 1 2
N O  H E D G E H O G  S I G N A L I N G  I N  A T H E R O S C L E R O T I C  P L A Q U E S
raising questions about the activity of
HH signal transduction in atherosclerotic
plaques and how plaque stability can be
maintained despite the neoangiogenic in-
fluence expected from the high levels of
HH ligands detected in plaques.
Absence of HH Signaling Despite
Ligand Expression in Atherosclerotic
Plaques
We investigated whether the presence
of HH ligand in atherosclerotic plaques
correlated with HH pathway activity. To
this end, atherosclerotic carotid plaques
obtained from 24 patients were investi-
gated for PTCH1 and GLI1 expression. In-
terestingly, PTCH1 and GLI1 expression
(Figure 3A) was very low in atheroscle-
rotic plaques, especially when compared
with healthy vessels. More importantly,
the expression levels of PTCH1 and GLI1
did not correlate with the expression lev-
els of HH ligands, as shown in Figures 3B
and C. In agreement, Western blot analy-
sis indicated that these samples contain
undetectable levels or only weak traces of
HH pathway targets (Figure 3D). Thus,
despite the presence of abundant HH lig-
and in atherosclerotic plaques, this pres-
ence does not translate into activation of
the HH pathway. From this result, we can
infer the existence of mechanisms that
limit activation of this signaling in
plaques.
Lipoproteins are important con-
stituents of atherosclerotic plaques and
are potentially important carriers of en-
dogenous HH antagonists (31). Conse-
quently, we investigated the presence of
vitamin D3 in the different lipoprotein
components of the blood of healthy vol-
unteers (Figure 3E). Interestingly, low-
density lipoprotein (LDL) contains sig-
nificant levels of Smoothened inhibitory
vitamin D3. Because LDL is important in
plaque formation, it is possible that the
thus-derived local availability of vitamin
D3 (or alternative hydroxysterols, which
inhibit HH signaling irrespective of the
presence of HH [29]) exerts a local nega-
tive effect on HH signaling, explaining
the remarkable dichotomy in HH signal-
ing between healthy vessels and athero-
sclerotic plaque. Because HH is an im-
portant mediator of revascularization
and revascularization is the major cause
of plaque instability, it is possible that
the lipoprotein compartment exerts mul-
tilevel influence on the pathological con-
sequences of thrombotic complications.
Hence, we propose that enhanced under-
standing of the interaction between HH
signaling and vascular biology will sub-
stantially contribute to our comprehen-
sion of the pathogenesis of cardiovascu-
lar disease.
DISCUSSION
Although most people develop athero-
sclerotic plaque from a young age (32),
most often these plaque do not rupture.
Among the factors that predispose indi-
viduals to rupture are neovasculariza-
tion, and thus understanding the mecha-
nisms that control such neoangiogenesis
are important. HH signaling is among
the most important signals controlling
neoangiogenesis, and this consideration
prompted us to investigate HH signaling
in both healthy vessels and atheroscle-
rotic plaque. We observed strong consti-
tutive activation of HH signal transduc-
tion in healthy human vessels, which is
required for survival of primary human
endothelial cultures. This result is in per-
fect agreement with the observation that
HH is important for the maintenance of
the endothelial compartment per se in ex-
perimental rodents (30). Importantly,
however, activation of HH signaling
seems to be dichotomous; in atheroscle-
rotic plaques, such signaling is not ob-
served. Because the absence of HH sig-
naling in plaques is expected to inhibit
revascularization of such plaques, we
propose that the inhibition of HH signal-
ing in plaque material contributes to
plaque stability and constitutes a protec-
tive signal (33).
CONCLUSION
The mechanism maintaining low activ-
ity of HH signaling in plaque remains
unclear, but does not involve the absence
of HH ligand, since ample amounts of
HH protein and RNA are detected in
 atherosclerotic structures. Interestingly,
we did observe that (especially on the
mRNA level) HH levels in healthy ves-
sels are increased compared with athero-
sclerotic plaques. One could thus argue
that the amount of HH in plaques is not
enough to robustly activate the pathway.
However, such a threshold hypothesis is
not likely for morphogens that are ex-
pected to act in response to low gradi-
ents of ligand. More likely, the low activ-
ity of HH signaling in plaques must
constitute inhibition downstream of the
primary HH receptor Patched (7,9).
Smoothened antagonists can inhibit HH
signal transduction downstream of
Patched and are thus obvious candidates
to participate in the HH signaling di-
chotomy. As lipoproteins constitute im-
portant components of the plaque struc-
ture, the presence of HH antagonists in
lipoproteins may negatively regulate HH
pathway activity. Interestingly, we did
find high levels of the Smoothened an-
tagonist 25-OH vitamin D3 in LDL. It is
tempting to propose that LDLs are Janus-
faced particles in atherosclerotic disease.
On one hand, LDLs contribute to plaque
formation, but on the other hand, they
contribute to plaque stability by carrying
antagonists of downstream HH signal-
ing. It is important, however, to point out
that other mechanisms, such as suppres-
sor of fused (SUFU) expression (7,34),
may also contribute to the functional di-
chotomy in HH signaling in the human
vasculature. Disregarding the exact
mechanism of HH signal transduction
inhibition in atherosclerotic plaques, it is
tempting to suggest that this inhibition
constitutes an important antipathogenic
signal and that enhanced knowledge of
the mechanisms involved may contribute
to better treatment and prevention of
atherosclerotic disease.
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